Gallacher Capital Management LLC Takes $286,000 Position in Doximity, Inc. $DOCS

Key Points

• Gallacher Capital Management LLC has acquired a new position in Doximity, Inc. valued at approximately $286,000, purchasing 4,662 shares during the second quarter.
• Insiders have sold a total of 32,000 shares of Doximity stock worth about $1.93 million over the past three months, with a notable decrease in their ownership percentages.
• Wall Street analysts have mixed opinions on Doximity, with a consensus rating of "Moderate Buy" and varying price targets, ranging from $59.00 to $75.00.

Gallacher Capital Management LLC bought a new stake in Doximity, Inc. (NASDAQ:DOCS - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 4,662 shares of the company's stock, valued at approximately $286,000.

Several other hedge funds also recently bought and sold shares of the stock. VSM Wealth Advisory LLC purchased a new stake in shares of Doximity in the first quarter valued at $29,000. Allworth Financial LP raised its stake in Doximity by 104.0% in the 1st quarter. Allworth Financial LP now owns 563 shares of the company's stock valued at $32,000 after purchasing an additional 287 shares during the last quarter. National Bank of Canada FI purchased a new position in Doximity in the 1st quarter valued at about $33,000. Spire Wealth Management boosted its stake in shares of Doximity by 73.2% during the 1st quarter. Spire Wealth Management now owns 615 shares of the company's stock worth $36,000 after purchasing an additional 260 shares during the last quarter. Finally, Brooklyn Investment Group grew its holdings in shares of Doximity by 70.7% during the first quarter. Brooklyn Investment Group now owns 746 shares of the company's stock worth $43,000 after buying an additional 309 shares in the last quarter. Hedge funds and other institutional investors own 87.19% of the company's stock.

Insider Buying and Selling at Doximity

In other news, Director Kira Scherer Wampler sold 2,000 shares of the company's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $57.09, for a total value of $114,180.00. Following the completion of the sale, the director owned 16,618 shares of the company's stock, valued at $948,721.62. This represents a 10.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Regina M. Benjamin sold 10,000 shares of the business's stock in a transaction that occurred on Wednesday, June 25th. The stock was sold at an average price of $60.00, for a total value of $600,000.00. Following the transaction, the director directly owned 16,618 shares in the company, valued at $997,080. This trade represents a 37.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 32,000 shares of company stock valued at $1,929,380 over the last three months. 31.30% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

DOCS has been the topic of a number of analyst reports. Zacks Research lowered shares of Doximity from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 20th. Needham & Company LLC upped their target price on Doximity from $67.00 to $75.00 and gave the company a "buy" rating in a research note on Friday, August 8th. JPMorgan Chase & Co. decreased their price target on Doximity from $63.00 to $60.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 27th. Canaccord Genuity Group upped their price objective on shares of Doximity from $50.00 to $59.00 and gave the company a "hold" rating in a research note on Friday, August 8th. Finally, Wells Fargo & Company increased their price objective on shares of Doximity from $55.00 to $62.00 and gave the stock an "equal weight" rating in a report on Monday, August 4th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and eleven have given a Hold rating to the company. According to MarketBeat, Doximity has an average rating of "Moderate Buy" and a consensus target price of $67.00.

Doximity Stock Performance

DOCS opened at $72.49 on Tuesday. Doximity, Inc. has a 1 year low of $39.27 and a 1 year high of $85.21. The firm has a 50 day moving average price of $63.84 and a 200 day moving average price of $59.78. The company has a market cap of $13.58 billion, a PE ratio of 72.49, a price-to-earnings-growth ratio of 4.10 and a beta of 1.37.

Doximity (NASDAQ:DOCS - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.36 earnings per share for the quarter, beating analysts' consensus estimates of $0.31 by $0.05. Doximity had a net margin of 36.60% and a return on equity of 21.75%. During the same quarter in the previous year, the business earned $0.28 EPS. The company's quarterly revenue was up 15.2% on a year-over-year basis. Doximity has set its FY 2026 guidance at EPS. Q2 2026 guidance at EPS. On average, sell-side analysts predict that Doximity, Inc. will post 0.99 earnings per share for the current year.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.

Want to see what other hedge funds are holding DOCS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Doximity, Inc. (NASDAQ:DOCS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.